{"id":"NCT01093651","sponsor":"Washington University School of Medicine","briefTitle":"Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV","officialTitle":"A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-06","primaryCompletion":"2011-06","completion":"2012-06","firstPosted":"2010-03-26","resultsPosted":"2014-01-23","lastUpdate":"2014-02-17"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":null},"conditions":["Diabetes","Insulin Resistance"],"interventions":[{"type":"DRUG","name":"Sitagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"DPPIV inhibition","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living with HIV.","primaryOutcome":{"measure":"CD4+ T-cell Count","timeFrame":"Monthly for 4 months","effectByArm":[{"arm":"Placebo","deltaMin":602,"sd":91},{"arm":"DPPIV Inhibition","deltaMin":648,"sd":185}],"pValues":[{"comp":"OG000 vs OG001","p":">0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23264399"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["Upper respiratory symptoms","Gastrointestinal symptoms","Headache","Generalized fatigue","Mood change"]}}